CassandraBio
Pipeline dossier

NIH & clinical-trial pipeline signals for Kailera Therapeutics, Inc. (KLRA)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for KLRA, mapped to public ticker KLRA (CIK 0002096997). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →
Trial → FilingKLRA35% conf

Kailera Therapeutics, Inc. (KLRA) — PHASE3 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)
trial ↗filings ↗
Trial → FilingKLRA35% conf

Kailera Therapeutics, Inc. (KLRA) — PHASE3 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)
trial ↗filings ↗
Trial → FilingKLRA35% conf

Kailera Therapeutics, Inc. (KLRA) — PHASE3 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)
trial ↗filings ↗
Trial → FilingKLRA35% conf

Kailera Therapeutics, Inc. (KLRA) — PHASE2 protocol updated 5 days ago

Upstream (observed)
Clinical trial status (PHASE2) — Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)
trial ↗filings ↗

Recent SEC 8-K filings

JSON API for this entity →